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Background: In 2009, 665 patients underwent total knee replacements (TKRs) at the Norfolk and Norwich
University Hospitals NHS Foundation Trust (NNUH), representing nearly 1% of the national total. Pain control
following the operation can be poor, and this can cause poor mobilization and potential long-term adverse events.
Although high levels of pain are not associated with patient dissatisfaction, brief periods of pain may lead to
neuronal remodeling and sensitization. Patient controlled oral analgesia (PCOA) may improve pain relief; however,
the evidence to date has been inconclusive. Patient directed self management of pain (PaDSMaP) is a single center
randomized controlled trial, which aims to establish if patient self-medication improves, or is equivalent to,
treatment as usual and to create an educational package to allow implementation elsewhere.
Methods/design: Patients eligible for a TKR will be recruited and randomized in the outpatient clinic. All patients
will undergo their operations according to normal clinical practice but will be randomized into two groups. Once
oral medication has commenced, one group will have pain relief administered by nursing staff in the usual way
(treatment as usual; TAU), whilst the second group will self manage their pain medication (patient directed self
management of pain; PaDSMaP). Those recruited for self-medication will undergo a training program to teach the
use of oral analgesics according to the World Health Organization (WHO) pain cascade and how to complete the
study documentation. The primary endpoint of the trial is the visual analogue scale (VAS) pain score at 3 days or
discharge, whichever is sooner. The follow-up time is 6 weeks with a planned trial period of 3 years. The secondary
objectives are satisfaction with the management of patient pain post-operatively whilst an inpatient after primary
TKR; overall pain levels and pain on mobilization; satisfaction with pain management information provided; global
outcomes, such as quality of life (QOL) and activities of daily living (ADLs); time to mobilization and whether time
to mobilization is associated with frequency of adverse events, improvements in QOL, ADLs and pain at 6 weeks
after the operation; incidence of adverse events; quantity and type of pain medications used whilst an inpatient;
the acceptability of PaDSMaP and/or TAU protocols for patients and the healthcare professionals involved in their
care; to investigate the health-related costs associated with a PaDSMaP system; and to estimate the
cost-effectiveness of PaDSMaP compared to TAU.
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In the four years to 2007 to 2008, the number of primary
total knee replacements (TKRs) increased by 163% to
73,455 in England and Wales. These figures are expected
to continue increasing owing to the ageing demographic
of the UK population [1] and the ability of TKRs to be
conducted with good outcomes in the very elderly (>80
years of age) [2]. In 2009, 665 patients underwent TKR
operations at the Norfolk and Norwich University Hos-
pitals NHS Foundation Trust (NNUH), representing
nearly 1% of the national total.
After a TKR operation, patients experience substantial
pain but there is debate on the best way to manage it [3,4].
Poorly controlled post-operative pain can have significant
and potentially long-term adverse effects on patients. Pain
can prevent early mobilization, which substantially raises
the risk of patients developing deep vein thromboses [5].
Even brief intervals of acute pain can induce long-term
neuronal remodeling and sensitization (‘plasticity’), chronic
pain, and lasting psychological distress [6,7]. However,
paradoxically, high levels of pain are not associated with
patient dissatisfaction with their pain management [8].
The World Health Organization (WHO) introduced
the concept of the analgesic ladder [9]. Under this regi-
men analgesics are introduced as follows:
 Step one: Non-opioid analgesics. For example
aspirin, paracetamol, non-steroidal anti-
inflammatory drugs (NSAIDs). If anticipation of
pain can be abolished, it may not be necessary to
step up to opioids. Give non-opioid regularly and
use adjuvants if necessary.
 Step two: Mild opioids. For example codeine,
dihydrocodeine; with or without non-opioid.
 Step three: Strong opioids. For example morphine
(Oramorph); with or without non-opioid.
The WHO guidelines for pain management state that
the evidence now suggests that pain can be best mana-
ged when drugs are taken ‘by the clock’ [9]. However,
any breakthrough pain should also be treated promptly
and effectively. Therefore adequate monitoring of pain
levels is a key principle of pain management and all par-
ticipants in this trial will be encouraged to monitor their
pain at least three times a day. Although the WHO pain
control ladder was originally designed for chronic cancer
pain, its principles have since been applied to acute pain
and have been adapted to accommodate modern analge-
sics, including adjuvant analgesics [10].
It is further proposed that a patient’s level of pain and
satisfaction with care may be influenced by who delivers
pain control medications, whether it is patient directed
(patient directed self management of pain; PaDSMaP) or
under nurse control (treatment as usual; TAU). The ‘bythe clock’ analgesia regimen may be more easily followed
in patient controlled oral analgesic (PCOA) protocols. It
is proposed that PCOA may also allow patients to vary
their analgesia more easily according to pain and activity
levels, for example in advance of mobilization. In
addition, since pain is a combination of tissue damage
and emotional state, it is hypothesized that being in con-
trol via self-medication may reduce the emotional com-
ponent of pain. It is known that psychological resilience
and preparedness make it easier to control pain [11,12].
However, there is limited and divergent evidence for
the efficacy and acceptability of PCOA. Two studies by
Striebel [13,14] claimed PCOA increased patient satis-
faction and pain control. In contrast, a recent pilot study
of PCOA provided on just the second post-operative day
after TKR showed no significant differences between the
PCOA and nurse controlled analgesia groups [15].
Patient understanding about analgesia is critical for ad-
herence, since it has been found that patients take fewer
analgesics than prescribed post-operatively, even if they
report a high level of pain [16,17]. Patients on patient
controlled analgesia (PCA, usually via infusion) reported
controlling the use of analgesics to balance side-effects,
self-image and pain [18]. Thus, the use of analgesics by
patients is not as simple as ‘just’ controlling pain levels.
Post-operative pain management at the NNUH will be
given by an initial ‘by the clock’ approach to medicating,
to prevent pain before it resurfaces. Ongoing monitoring
of the pain will take place to ensure there is no break-
through pain and then either additional ‘as needed’ doses
or downward titrations of the initial dosage, depending
on pain levels, can be administered. This type of pro-
posed schedule is consistent with the flexibility recom-
mendations of the Agency for Healthcare Research and
Quality (AHRQ) [19].
Therefore, the information provided to participants
should cover issues of importance to them [20], including
expectations of the pain experience, the analgesic plan,
the importance of a ‘by-the-clock’ approach, management
of analgesic side-effects and non-pharmacological meth-
ods of pain control [4,18].
This study’s PaDSMaP intervention addresses the key
aim of the Darzi Report [21]: ‘An NHS that gives patients
and the public more information and choice, works in
partnership and has quality of care at its heart’.
Primary objective
To investigate if PaDSMaP reduces pain at 3 days or on
discharge, whichever is sooner, after primary TKR oper-
ation compared to TAU.
Secondary objectives
To investigate whether the PaDSMaP and TAU groups
differ in terms of:
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pain post-operatively whilst an inpatient after
primary TKR.
 Overall pain levels and pain on mobilization.
 Satisfaction with pain control.
 Satisfaction with pain management information
provided.
 More global outcomes, such as quality of life (QOL)
and activities of daily living (ADLs).
 Time to mobilization, and whether time to
mobilization is associated with frequency of adverse
events, and improvements in ADLs, QOL and pain
at 6 weeks after the operation.
 Incidence of adverse events.
 Quantity and type of pain medications used whilst
inpatients.
Additional secondary objectives include: to investigate
the acceptability of the PaDSMaP and TAU protocols for
patients and the healthcare professionals involved in
their care; to investigate the health-related costs asso-
ciated with a PaDSMaP system; and to estimate the
cost-effectiveness of PaDSMaP compared to TAU.
Methods
Ethics approval
This study has been approved by the Cambridgeshire 1
Research Ethics Committee approval Ref: 10/H0304/52.
The study will be conducted in full conformity with the
current revision of the Declaration of Helsinki (last
amended October 2000, with additional footnotes added
2002 and 2004), and in full conformity with relevant reg-
ulations and the International Conference on Harmon-
isation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) Guidelines for
Good Clinical Practice, CPMP/ICH/135/95, July 1996.
A research nurse from the study team will meet with
the patient at the pre-operative assessment clinic (2 to 3
weeks prior to operation) and make a final check on trial
eligibility. Written and verbal versions of the participant
information leaflet will then be presented detailing the
exact nature of the study. In particular, the research
nurse will explain the randomized allocation element of
the trial. It will be made clear that the patient is free to
withdraw from the study at any time for any reason
without prejudice to future care, and with no obligation
to give the reason for withdrawal. The patient will be
allowed as much time as they wish to consider the infor-
mation and ask questions. If required, the research nurse
will facilitate opportunities to question other members
of the research team, the patient’s general practitioner
(GP) or other independent parties, to decide whether
the patient can participate in the study. This may mean
that the research nurse has to arrange a subsequenthome visit at a later date after prior agreement and ar-
rangement with the patient.
Written informed consent will be obtained by means of
a participant dated signature and dated signature of the
research nurse. These signatures will be obtained on the
latest approved version of the informed consent form,
before any study-specific procedures are performed. A
copy of the signed informed consent will be given to the
participant and a copy will be retained by the Trial Office
at the University of East Anglia (UEA). The original
signed form will be sent to the participant’s GP.
For those participants recruited into the qualitative
interview aspect of the trial, a further information sheet
will be given and a consent form will subsequently be
completed and signed. As above, a copy will be given to
the participant and a second copy will be retained by the
Trial Office at the UEA.
All data will be handled in accordance with the Data
Protection Act 1998, which requires data to be anon-
ymized as soon as it is practical to do so. Each partici-
pant will have a case record file containing copies of
consent forms, completed measures and demographic
information. Case record files will be kept in a locked
cabinet within a locked room at NNUH. Only the chief
investigator (RG), the project lead (KD) and the research
nurse will have access to these. Both RG and KD have
extensive experience of clinical trials, and RG and KD
are trained in the ICH and WHO Good Clinical Practice
Standards for Clinical Trials.
The trial staff will ensure that the participants’ ano-
nymity is maintained. The participants will be identified
only by initials and a participant ID number on case re-
port forms and electronic databases. All documents will
be stored securely and will only be accessible by trial
staff and authorized personnel.
Trial design
Summary of trial design
This study uses a prospective, randomized, parallel-
group design to compare PaDSMaP to TAU for patients
undergoing a primary unilateral TKR at a teaching hos-
pital, the NNUH. The analysis of clinical outcomes will
be blinded. It will not be possible to blind the health
economic data analysis.
One hundred and forty-four patients who have just
undergone TKR will be randomly assigned to the PaDS-
MaP or TAU groups pre-operatively. This study will in-
vestigate whether PaDSMaP improves levels of pain at 3
days or discharge, whichever is sooner, after a TKR oper-
ation, compared to TAU. It will also compare the two
groups up to 6 weeks after the operation for pain levels,
satisfaction with the control of pain, return to walking
and normal activities, as well as any further problems.
We will also interview a sample of 12 patients (six
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sionals involved in their care, to explore their experi-
ences of the PaDSMaP and TAU protocols. Finally, we
will measure the costs of PaDSMaP compared to those
of TAU.
In addition, the patients entered into this study will
form a group that will be followed up in standard nurse-
led remote follow-up clinics for up to 5 years, to deter-
mine the impact of pre-operative characteristics (such as
anxiety, depression, pain levels) and levels of post-
operative pain control on the long-term success or fail-
ure of TKRs, as defined by the development of chronic
pain, return to normal activities and impact on QOL.
Primary and secondary outcome measures
The primary outcome for PaDSMaP is pain levels at dis-
charge or after 3 days, whichever is sooner, after primary
unilateral TKR in patients, as measured by a 10 cm con-
tinuous visual analogue scale (VAS).
Secondary outcome measures for the patients comprise:
 Pain levels (pre-operative assessment clinic baseline
(2 to 3 weeks prior to operation), Days 1 to 3 and 6
weeks post-operatively).
 Pain after mobilization (3 times a day for Days 1 to
3 post-operatively).
 Satisfaction with pain levels (Days 1 to 3 and 6
weeks post-operatively).
 Satisfaction with Information about Medicines Scale
(SIMS) (Day 3 and 6 weeks post-operatively).
 EuroQoL EQ-5D questionnaire (EQ-5D) (pre-
operative assessment clinic baseline, 6 weeks post-
operatively).
 Oxford Knee Score (OKS) (pre-operative assessment
clinic baseline, 6 weeks post-operatively).Table 1 Patient outcome measures time points
Patient outcomes Baseline Post-operative
Day 1
Pain VAS x Breakfast, lunch, supper
Pain VAS after mobilization x




Time to mobilization x
Adverse events x x
Medication usage3 x x
Health resource use questionnaire x
Qualitative interviews*
*Subsample of five patients from each group; 1Completed at lunchtime and at disch
anaesthetic agents (except inhaled anaesthetics). VAS, visual analogue scale; SIMS, S
questionnaire; OKS, Oxford Knee Score. Time to mobilization (inpatient notes).
 Adverse events (Days 1 to 3 and 6 weeks post-
operatively).
 Medication usage (pre-operative assessment clinic
baseline, Days 1 to 3 and 6 weeks post-operatively).
 A health resource use questionnaire (pre-operative
assessment clinic baseline, 6 weeks post-operatively).
 Qualitative evaluation of patients’ and health
professionals’ experiences (five patients from each
group 6 weeks post-operatively and ten healthcare
professionals after trial protocol has finished).
See Table 1.
Trial participants
The study is aimed at patients who are about to undergo
a primary unilateral TKR. We will recruit patients re-
ferred to the orthopaedic clinics for TKR at the NNUH.
Inclusion criteria
 All adult patients aged over 18 years undergoing a
primary TKR operation.
 Meet the NNUH self management of pain criteria.
 Are expected to require standard step 1 to 3 oral
analgesics post-operatively
 Post-operatively, patients must be awake and
breathing independently, able to answer questions
and follow commands to continue in the protocol.
 Are English speaking and literate. (We expect the
patient participants to be able to read the
information sheet for the PaDSMaP protocol and fill
in a number of self-assessments. Less than 1% of the
population over the age of 50 years, which are the
usual candidates for TKRs, are non-English speaking
in our catchment area.)Post-operative
Day 2
Post-operative















arge; 2Completed at discharge; 3All medications in last 24 hours, including
atisfaction with Information about Medicines Scale; EQ-5D, EuroQoL EQ-5D
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epidural analgesia and will start PaDSMaP or TAU
as soon as they begin oral analgesia.
Exclusion criteria
 Expected to require intensive care.
 Known, or suspected to be, opioid tolerant or
dependent.
 Regular users of any modified release opiate
preparation during the 2 weeks prior to TKR.
 Recent history of drug or alcohol abuse.
 Lack competence to consent by reason of dementia
or any other reason.
 Any patient who does not self-administer at home.
These inclusion and exclusion criteria are in line with
the NNUH’s drug self-administration policy.
Study procedures
Recruitment Patients eligible for a primary TKR will be
given an information sheet and consent form at the out-
patient clinic where the patient is added to the TKR
waiting list (approximately 6 weeks prior to operation).
In addition, any potential participant who is missed from
this clinic, but is placed on the TKR waiting list, will also
be sent an information sheet and consent form by post.
A phone call from the research nurse will be made to
eligible patients approximately 1 week prior to the pre-
operative assessment clinic. The purpose of this phone
call is to determine if the patient is interested in partici-
pating in the PaDSMaP study. The phone call will not
be regarded as confirmation of patient consent to par-
ticipate in the study; consent will be taken during the
clinical appointment. The purpose of the call is to en-
sure that the research nurse is available to appropriately
conduct consent and carry out baseline measures and
education on the PaDSMaP protocol, as appropriate.
Recruitment and informed consent for interviews Six
patients from each group will be purposively sampled to
participate in interviews to assess the acceptability of the
PaDSMaP and TAU protocols. The patients will be pur-
posively selected according to pre- and post-operative
characteristics that may have had an impact on their ex-
perience of the pain control protocols (for example age,
pain levels after TKR, length of stay).
The selected patients will be sent separate information
sheets and consent forms for this section of the research
protocol at least 1 week prior to their 6 week follow-up
outpatient appointment by the research nurse. At this
appointment the research nurse will explain the inter-
view process, the arrangements for the interview and en-
sure the patient understands the patient informationleaflet for interview detailing the exact nature of the inter-
views. Again it will be made clear that the patient is free
to withdraw from the study at any time for any reason
without prejudice to future care, and with no obligation to
give the reason for withdrawal. The patient will be allowed
as much time as they wish to consider the information
and ask questions. If consent is given, the research nurse
will organize an appointment for the interview. The inter-
view can take place at the patient’s home or in a private
room at the hospital, whichever is the patient’s preference.
Should the patient withdraw from the interview at the
time it is undertaken, the data will not be used. Once an
interview transcript has been received by the patient for
checking they will then have a 2 week period to withdraw
from this section of the study, or it will be presumed that
that the transcript can be used.
Twelve healthcare professionals, representative of the
team that looks after patients after a TKR, will also be
purposively selected to participate in interviews to inves-
tigate their views on the PaDSMaP and TAU protocols.
These interviews will be held after the majority of
patients we aim to recruit have passed through the
PaDSMaP protocol. The healthcare professionals will be
sent information sheets and consent forms. The research
nurse will then contact them to ask if they would be
willing to participate in the interview.
If they indicate they are willing, an appointment will be
made to meet with the research nurse during working
hours in a private room at the hospital. The research
nurse will explain the interview process, the arrangements
for the interview and ensure the healthcare professional
understands the healthcare professional information leaf-
let detailing the exact nature of the interviews. It will be
made clear that the healthcare professional is free to with-
draw from the interview at any time for any reason and
with no obligation to give the reason for withdrawal. If
written consent is provided, the interview will proceed.
Withdrawal from the study will be on the same basis as
the patient interviews.
Assessments When consent has been obtained the re-
search nurse will collect baseline data from patients. The
research nurse will be trained in administering question-
naires in a standardized way. The majority of the out-
comes will be self-completed by the patients. The research
nurse will regularly visit the orthopaedic wards to encour-
age completion of the questionnaires by patients in both
arms of the trial. The following information will be
obtained.
Primary outcome
Pain VAS (visual analogue scale)
Pain levels will be measured using a 10 cm continuous
VAS bounded by the phrases ‘no pain’ and ‘worst
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dicate where their pain level over the previous 4 hours
lies. This will be measured at the end of Day 3 post-
operatively or at discharge, whichever is sooner.
Secondary outcomes
Pain VAS
Pain VAS for the previous 4 hours will also be measured
at a variety of time points (at baseline, post-operative
Days 1 to 3 at breakfast, lunch and supper, and at the 6
week follow-up clinic; see Table 1), to determine the pat-
tern of pain pre- and post-operatively. We will also
measure current pain levels on a 10 cm VAS after
mobilization with the physiotherapist. Finally, patients
will be asked to note if pain was sufficient to wake them
during the night (Yes/No answer).
Patient satisfaction with pain control
Patients will indicate their satisfaction with the control
of their pain on a five-point Likert-type scale. They will
indicate the degree to which they agree or disagree with
statements about their satisfaction with the control of
their pain.
Satisfaction with Information about Medicines Scale (SIMS)
Patients will indicate their satisfaction with the informa-
tion they received on a validated 17-item tool, designed to
assess the extent to which patients feel they have received
enough information about prescribed medicines [23].
Oxford Knee Score (OKS)
The OKS was designed for the assessment of TKR out-
comes [24]. The score is derived from a 12-item question-
naire which is self-administered by the patient.
Importantly, the questions were designed with input from
patients themselves in order to try to ensure that the in-
formation derived was as valid and sensitive as possible.
This score appears to be simple and reliable, as well as
being sensitive to clinically-important changes over time
within one patient. This score is also part of the patient
reported outcome measures (PROMs) package [25].
EuroQoL EQ-5D questionnaire (EQ-5D)
The EQ-5D [26] is a widely used generic utility measure,
which is used to characterize current health states. It
consists of five dimensions, which each have three levels
and a VAS. This measure will be used in the cost-
effectiveness analysis (Brooks 1996), where responses
will be sought at baseline and 6 weeks post-operatively.
This will subsequently enable the quality-adjusted life
year (QALY) gain associated with the intervention to be
calculated. The EQ-5D is being used as part of the
PROMs package nationally to track outcomes of TKRs
[24].Time to mobilization
The information regarding the time and day that the pa-
tient is able to stand up and transfer from bed to chair
will be taken from the notes by the research nurse onto
the case report form.
Adverse events
Adverse events will be identified by self-completed reports
from patients and from patient notes by the research nurse
on the case report form. These will be reported regularly
and discussed with the clinical lead (SD), the Data Moni-
toring and Ethics Committee (DMEC) chair (Dr Sanders)
and, where appropriate, with the governance lead for the
Trust. Adverse events will be recorded from the point
patients are entered into the study (at randomization in
the pre-operative assessment clinic) to the point at which
they leave the study (the 6 week follow-up clinic).
Medication usage
All medications that are used by the participants in the
study will be documented. At baseline, all medications
and dosages currently taken by the patient will be
recorded, particularly those used for pain relief. During
the hospital inpatient stay participants in the PaDSMaP
group will be asked to note the type of pain relief medi-
cation they took, the dose and the exact time at which
they took it on the inpatient prescription chart. Digital
illuminated clocks will be provided in the drug boxes for
the PaDSMaP group. Nurses looking after patients in
the TAU group will be asked to note the exact time of
delivery of the analgesic drugs on the inpatient prescrip-
tion chart. At the 6 week follow-up, patients will be
asked to report their current medication usage.
Healthcare related costs
In line with guidance from the National Institute for
Health and Clinical Excellence (NICE) [27], costs will first
be calculated from the perspective of the National Health
Service (NHS) and personal social services, and encom-
pass those costs that are potentially related to the inter-
vention in question. Costs of the intervention, for
example training the nurses, training the patients and
provision of locked medication boxes will be recorded.
Levels of resource use incurred in the 6 weeks post-
randomization will be recorded, including use of medica-
tions, pharmacy costs, the length of original hospital stay,
input by healthcare professionals in hospital (for example
ward nurse time, physiotherapists) and subsequent out-
patient or GP visits post-discharge. Unit costs will subse-
quently be assigned to each of these resource items.
Baseline characterization of the population
The following measures regarding the character of the
recruited population will also be collected at baseline.
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 Whether there will be someone to assist the patient
on discharge (for example spouse or carer).
 Whether the residence the patient will be
discharged to has stairs.
 Level of education.
 Socioeconomic status (estimated using participants’
postcodes).
 Body mass index (BMI, from notes).
 Duration of knee pain.
 Current level of knee pain (VAS).
 Previous experience of orthopaedic surgery (what
and when).
 Expectation of level of pain post-operatively at Days
1 to 3 and week 6 (VAS).
 Medication profile (type of medications, dosage level
and frequency).
 Comorbidities.
 Other musculoskeletal problems.
 Surgical procedures undertaken in TKR (surgical
procedure questions).
 Hospital Anxiety and Depression Scale (HADS).
 Beliefs about Medications Questionnaire (BMQ).Surgical procedure questions
Surgical procedure questions will be gathered as part of
standard practice for the National Joint Registry (NJR)
[28]. They will allow us to determine if the type of surgi-
cal procedure had a bearing on patients’ pain and
recovery.Hospital Anxiety and Depression Scale (HADS)
The HADS [29] identifies anxiety disorders and depres-
sion, and has been widely used and validated [30].
Anxiety and depression have been identified as factors
that can affect post-operative pain and recovery [11].
Should the HADS identify depression, this information
will be fed back to the patient immediately along with
one of two information sheets that recommends the
patient to contact their GP (moderate/severe depres-
sion) or refers the patient to relevant self-help websites
(mild depression). A letter will also be sent (with the
patient’s knowledge) to their GP informing them that
the patient has been identified as having depression
and informing them of what recommendations the re-
search team has made to the patient.Beliefs about Medications Questionnaire (BMQ)
This BMQ [31] will be used to measure patients’ atti-
tudes and beliefs toward medication. Since these patients
will be prescribed multiple drugs the general version of
the measure will be used. Each item is rated on a five-
point Likert-type scale ranging from ‘strongly disagree’
(1) to ‘strongly agree’ (5). The questionnaire has four
sections that evaluate attitudes about:
1. General harm (G-H) that is, the intrinsically harmful
properties of medications (four questions, such as
‘most medicines are addictive’).
2. General overuse (G-O) of medications by healthcare
professionals (four questions, such as ‘Doctors use
too many medicines’).
3. General sensitivity (G-S) to adverse events from
medications (five questions, such as ‘my body is very
sensitive to medicines’).
4. General benefit (G-B) that is, the intrinsically
beneficial properties of medications (four questions,
such as ‘in most cases the benefit of medicines
outweigh the risks’).
Randomization
The research nurse will check patient eligibility and con-
sent against a checklist. Authorized research nurses will
each be allocated a six-digit personal identification
number (PIN) for use when randomizing patients. The
research nurse will telephone the independent
randomization service at the Clinical Research and Trials
Unit (CRTU) at the UEA. The system will request the PIN
and will only proceed if a valid PIN is entered via the tele-
phone keypad.
On entry of a valid PIN, the system will generate a
unique study code and randomly allocate the patient to
either the PaDSMaP or TAU arm of the trial. The study
code and allocation will be reported back to the caller
verbally and will also be sent in a confirming email to: a)
the caller, b) other nominated trial staff and c) the trial
database manager. The study code and allocation will be
stored in the trial database on the secure CRTU server
at UEA.
A computer generated randomization list will allocate
patients in a 1:1 ratio to PaDSMaP or TAU groups.
Randomization is unstratified. To ensure a reasonably
even distribution of patients in the two arms throughout
the course of the trial, patients will be allocated in ran-
domly distributed blocks of four and six.
At the pre-operative assessment clinic, patients that
have expressed an interest in participating in the PaDS-
MaP study will go the CRTU after their clinic appoint-
ment. At CRTU they will be consented and randomized.
The baseline assessments will be conducted and patients
instructed on how to complete the trial inpatient outcome
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Patients in the TAU group will receive the standard gen-
eral information sheet and DVD outlining the TKR
operation and recommendations for both pre- and post-
operative exercises [32].
The study is a pragmatic trial and as such normal varia-
tions in pre- or post-operative anaesthetic are part of what
will be examined. The patient’s initial post-operative anal-
gesic care will be under the direction of the anaesthetists
and this normally lasts for 12 to 24 hours post-operatively.
Oral analgesia will be initiated prior to pain resurfacing
after, for example, the epidural has worn off. Patients’ oral
post-operative analgesia on the wards will be dispensed as
usual by the nursing team to the TAU group.
We expect that the majority of patients recruited to
this study will receive the Modified Caledonian Tech-
nique (MCT) Norwich Enhanced Recovery Program
(NERP). This program aims to enhance the recovery of
patients having primary knee replacements by a multi-
modal program, which facilitates early mobility and dis-
charge. The NERP focuses on the provision of safe and
effective analgesia with minimal side-effects, which then
enable early mobility. Of note, gabapentin is included
because it is an opioid-sparing medication and reduces
opioid-related side-effects [33].
Centers in the UK and abroad adopting the enhanced
recovery program have reduced patients’ length of stay
significantly. It is likely that the exact details of the
NERP will develop over the course of the trial. It should
also be noted that individual patients will always be
offered the most suitable protocol for their particular
circumstances, so some patients will not follow the
NERP protocol. Again this does not prove an obstacle,
since the study is a pragmatic trial and variations in care
are part of what is to be examined.
Enhanced recovery programs are multimodal and
focus on the following elements:
1. Educating GPs and community support services.
2. Patient education and support.
3. Pre-operative physiotherapy, and occupational
therapy assessment and education.
4. Pre-operative anaesthetic and surgical assessment.
5. Utilizing surgical and anaesthetic techniques, which
facilitate early mobility.
6. Excellent post-operative analgesia allowing early
patient mobilization.
7. Intensive post-operative physiotherapy.
8. Early discharge with appropriate back-up and
follow-up.Exemplar analgesic protocol
In pre-operative period
 Gabapentin 300 mg orally (2 hours before operation
or can be given the night before).
At commencement of the anaesthetic process
 Single shot spinal 2.5 to 3.0 ml bupivacaine plus
total continuous infusion (TCI) of propofol for
sedation (or a light general anaesthetic if
anaesthetist prefers).
 Ondansetron 4 mg intravenous (IV).
 Paracetamol 1 g IV.
 Dexamethasone 8 mg IV.
 Diclofenac 75 mg IV, if tolerated.
 Tranexamic acid (given to minimize blood loss; has
90 minute half-life so given just before tourniquet
goes down for TKR).
 No opiates.
 No urinary catheter.
 Limit fluids to approximately 1 litre intra-
operatively, if possible.
At end of operation
 Surgeon infiltrates joint space with 150 to 200 ml of
0.2% ropivacaine .
 Surgeon places clearly labeled catheter into the joint
space (periarticular catheter).
 Infusion set up with McKinley pump of ropivacaine
0.2%, 200 ml.
 Give 20 ml bolus and set pump at 5 ml per hour.
Post-operatively
 Gabapentin 300 mg twice a day for 5 days.
 Paracetamol 1 g orally four times a day.
 Ibuprofen 400 mg three times a day, if patient is
able to tolerate.
 Oxycodone (OxyContin) 10 to 20 mg twice a day
for 3 to 5 days.
 Morphine (Oramorph) 5 to 20 mg as needed up to
every 2 hours for breakthrough pain.
 Ondansetron 4 mg twice a day IV as needed.
 (Intramuscular morphine as needed for escape
analgesia is also prescribed.)
Exemplar physiotherapy protocol
Providing that the patient’s systolic blood pressure is
within 10% of its pre-operative reading, the patient will
be mobilized 4 hours after surgery (Day 0). If a patient
feels dizzy on attempting to mobilize, or their blood
pressure drops to below 80 mmHg systolic, oral ephe-
drine 30 mg (or intramuscular ephedrine if no oral ephe-
drine is available) is given and mobilization is attempted
again after 30 minutes.
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post-operative day. Once the patient is stable on
crutches without support, they will be encouraged to
mobilize independently. The patient will receive physio-
therapy three times a day until discharge.
Exemplar discharge protocol
If appropriate, the patient will be discharged on Day 3 to
4. The discharge criteria will be:
 Able to mobilize independently.
 Pain is well controlled on oral analgesics.
Patients will be discharged with 14 days of oral analge-
sics and informed that they must visit their GP for a fur-
ther prescription. The patient will be telephoned at
home on Day 7 post-discharge.
Development of the PaDSMaP package
Effective treatment of pain requires individually tailored
care pathways and treatment strategies. The PaDSMaP
package will be developed by members of the research
team in conjunction with relevant clinical and lay experts.
This will result in a comprehensive, structured, evidence-
based training manual with associated information in a
range of appropriate formats, capable of being tailored
according to individual needs, and designed for delivery by
a trained research nurse and the post-operative ward team.
Patients in the TAU group will receive the PaDSMaP pa-
tient information sheet, but all other aspects of their care
before, during, and after their TKR operation will be TAU.
Pre-operative education: PaDSMaP group
Patients will get a short break after the consent process
and baseline assessments are completed before they re-
ceive training in the PaDSMaP protocol. Patients will re-
ceive an information sheet and a DVD, which in addition
to the standard information on the operation and pre- and
post-operative exercises, will include information on the
PaDSMaP self-medication protocol. The research nurse
will then take 20 minutes to explain how to self-monitor
their pain and medicate it appropriately. Patients will re-
ceive protocols outlining how to maximize analgesia, how
they can adjust their analgesic levels, and receive informa-
tion prior to the operation about appropriate pain control
and why pain control is important (earlier mobilization,
reduction in adverse events, and so on).
The PaDSMaP information sheet covers the issues iden-
tified by Kastanias [20] as important to patients regarding
post-operative pain management. These will include:
 Expectations of the pain experience itself.
 What the analgesic plan is and what to do if it does
not work. Other ways of dealing with pain in addition to
medicine (relaxation and distraction techniques, ice
packs) [4,18].
 Side-effects of analgesics, both what to expect and
how to manage side-effects.
Post-operative analgesia
Patients in the PaDSMaP group will be in charge of their
post-operative oral analgesia. The patients will have a
lockable drugs cabinet at their bedside that is easily ac-
cessible to them. The drugs cabinet will contain 14 days’
supply of all of the drugs a patient is prescribed for self-
medication (all analgesics and the patient’s other usual
medications, but excluding any prescribed schedule
drugs, for example oxycodone). The drug boxes will be
resupplied on a daily basis to ensure 14 days’ supply is
available. The usual prescribed regimen will be as for
TAU post-operative oral analgesia:
 Gabapentin 300 mg twice a day for 5 days.
 Paracetamol 1 g orally four times a day.
 Ibuprofen 400 mg three times a day, if patient is
able to tolerate.
 Oxycodone (OxyContin) 10 to 20 mg twice a day
for 3 to 5 days.
 Morphine (Oramorph) 5 to 20 mg as needed up to
every 2 hours for breakthrough pain.
Some drugs, such as oxycodone (OxyContin), are not
approved for self-medication protocols at NNUH owing
to their being scheduled drugs. In the event that a
scheduled drug is prescribed, it will be delivered by the
ward nurse as part of their usual drug rounds. The
scheduled drug(s) will be the only drug(s) that patients
receive from the ward nurses; patients will self-medicate
with all other drugs.
Patients will be discharged with 14 days’ supply of
drugs. This will not usually include morphine (Ora-
morph) or oxycodone (OxyContin).
The WHO guidelines for pain management state that
the evidence now suggests that pain can be best mana-
ged when drugs are taken ‘by the clock’ and patients in
the PaDSMaP arm will be encouraged to do so. How-
ever, patients will also be encouraged to follow a pre-
specified protocol to treat breakthrough pain, that is a
combination of ‘by the clock’ and ‘as needed’ protocols.
Policy documents repeatedly state that adequate moni-
toring of pain levels is a key principle of pain manage-
ment and so PaDSMaP patients will be encouraged to
monitor their pain hourly. Thus, our plan is an initial ‘by
the clock’ approach to medicating (to prevent pain be-
fore it resurfaces), ongoing monitoring of the pain to en-
sure there is no breakthrough pain, and then either
additional ‘as needed’ doses or downward titrations of
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proposed schedule is consistent with the flexibility
recommendations of the AHRQ [19].
The ward nurses and pharmacists will also receive ap-
propriate training to support patients who are self man-
aging their pain.
Follow-up
Baseline measures of efficacy will be repeated at 6 weeks
post-operatively. This time-frame reflects the usual out-
patient follow-up clinic time point. The research nurse
will ensure completion of all self-assessment scales at this
outpatient clinic.
Analysis
Description of statistical methods
Primary and secondary outcomes will be compared be-
tween intervention and control groups using t-tests, non-
parametric tests or chi-squared and Fisher’s tests, as
appropriate. Where differences are observed between out-
come measures, demographics and patient characteristics
at baseline, adjusted effect sizes will be estimated using
linear models.
Baseline analyses
To assess external generalizability, demographic and
clinical characteristics of participants’ responses at the
baseline phase of the study will be compared with parti-
cipants who are subsequently randomized, and partici-
pants who are screened but not randomized. The
specific criteria by which participants are excluded from
randomization will be tabulated.
Number of participants
Seventy-two patients in each arm are sufficient to detect
a between-group difference of 0.5 standard deviations in
the VAS pain intensity with 80% power using an inde-
pendent samples t-test. Dahlen [34] reported a standard
deviation in VAS pain intensity score of 24 points 2 to 5
days after total knee arthroplasty and so assuming a
similar variability this represents a difference of about 12
points. Calculations use a significance level of 0.05. A
drop-out rate of 10% is expected and accounted for. One
hundred and forty-four patients will be randomized in a
one-to-one ratio.
Twelve patients from each arm and 12 healthcare pro-
fessionals will be interviewed to investigate acceptability.
The patients will be purposively selected according to
pre- and post-operative characteristics that may have an
impact on their experience of the pain control protocols
(for example age, pain levels after TKR, length of stay).
Team members will be selected to represent the
spectrum of healthcare professionals that come intocontact with patients after a TKR (for example nurses,
pharmacists, physiotherapists).
Feasibility of target sample size
In 2009, 665 patients had TKR operations at the NNUH.
The trial requires recruitment of 144 patients over 24
months, which represents approximately 11% of this
population, to meet the requirements of the power cal-
culation. In order to determine if this rate of recruitment
was feasible, a mock recruitment was conducted, asking
patients that would be eligible for the PaDSMaP trial
whether they would consider participation as part of
their pre-operative clinic interviews.
Allowing for patients being excluded, the planned re-
cruitment rate is six patients per month over a 24 month
period. This target will be reviewed after 6 months.
Efficacy analysis
The efficacy of the intervention on the primary outcome
(pain VAS) will be assessed by comparing outcomes at
discharge or 3 days post-operatively, whichever is sooner,
between the two groups. Adjusted estimates will be
obtained by identifying baseline variables, which differ
between the groups and which are related to the out-
come, and incorporating these into a regression analysis.
Inclusion in analysis
Both intention to treat (ITT) and per-protocol (PP) ana-
lyses will be performed. The ITT analysis set will com-
prise all patients who have been randomized to each
intervention, irrespective of their compliance with the
planned course of treatment. This is the primary analysis
and will be used for evaluation of all endpoints. The PP
set will include patients that have not deviated from the
protocol in such a manner that the assessment of effi-
cacy endpoints may be biased. Appropriate adjustments
will be made in the statistical analyses for potential con-
founding factors. These include age, gender, socioeco-
nomic status, level of knee pain pre-operatively, levels of
anxiety and depression.
Economic evaluation
The aim of the economic evaluation is to assess whether
PaDSMaP represents a cost-effective use of scarce NHS
resources when compared to TAU.
Measuring costs
In line with NICE guidance, costs will be calculated from
the perspective of the NHS and personal social services,
and encompass those costs that are potentially related to
the intervention in question. Thus, for all patients we
will monitor the levels of resource use associated with
the inpatient stay (including medication use), any re-
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example further therapy, nursing care, and so on).
Patient resource use will be obtained from responses
to a health resource use questionnaire at baseline and 6
weeks post-randomization. Appropriate unit costs
[35,36] will subsequently be assigned in order to calcu-
late total costs for PaDSMaP and TAU. For the PaDS-
MaP arm we will estimate the resource use associated
with training the research nurse, the ward nurses and
pharmacists, and the self-medicating patients. Also, any
additional time spent by the ward staff with the PaDS-
MaP patients related to them facilitating the self-
medication regimen will be monitored.
Measuring effects
The measure of effectiveness employed in the economic
analysis will be measured by the EQ-5D [37]. This is a
generic measure of health status designed to compare
the benefits of different interventions. It has five dimen-
sions: mobility, self-care, usual activities, pain and anx-
iety/depression. These will be used to calculate QALYs
associated with the intervention and TAU.
Potential bias
The subjective nature of the self-report instruments used
for evaluation of the intervention is accepted and every
effort will be made to minimize potential bias owing to
this dynamic. In particular, patients may over- or under-
report their health status depending on the trial arm to
which they have been assigned.
Economic analysis: cost-effectiveness analysis
We will estimate both the mean overall cost and mean
overall effect associated with PaDSMaP, compared to
TAU. If one of these options is shown to be less costly
and more effective than the other, then this would
suggest that it ‘dominates’ the other and represents a
cost-effective use of scarce resources. Alternatively, the
incremental cost-effectiveness ratio associated with
PaDSMaP will be estimated and assessed in relation to a
range of cost-effectiveness thresholds (for example
£20,000 to 30,000 per QALY [27]). The associated level
of uncertainty will also be characterized by estimating
the cost-effectiveness acceptability curve. Sensitivity ana-
lysis will also be undertaken to assess the robustness of
conclusions to changes in key assumptions.
Qualitative evaluation: qualitative investigation of
acceptability of the protocols to patients and staff
All patients will be asked to rate their satisfaction with
the information provided to them. A phenomenological
assessment of the two protocols will be conducted using
in depth semi-structured interviews undertaken with a
purposively selected subsample of patients (n = 12). Inaddition, healthcare professionals involved in delivering
the intervention will be interviewed to explore their per-
ceptions of the process of using PaDSMaP (n = 12). The
aim of these interviews will be to:
 Obtain insights into patients’ and health
professionals’ experiences of using the pain relief
protocols (PaDSMaP and TAU, as appropriate).
 Consider which elements of the PaDSMaP and/or
TAU were perceived as being most and least helpful.
 Explore the participants’ perceptions of the effect
that they think PaDSMaP and/or TAU protocols has
had on them.
 Uncover any potential barriers and roadblocks to
using the PaDSMaP and/or TAU protocols.
 Explore how the PaDSMaP and/or TAU protocols
could be refined and enhanced.
An interview schedule will be used for consistency and
to ensure coverage of all areas above deemed important.
Participants will be prepared for an interview of approxi-
mately 30 minutes. Following consent, the first inter-
views will be conducted by the research nurse and take
place at patients’ homes and other appropriate venues
(healthcare professionals). All interviews will be audio-
recorded, transcribed verbatim and sent to the partici-
pants for corroboration. Interviewees will be able to
adjust the transcript so that it reflects their views appro-
priately. Confirmed transcripts from all of the interviews
will then be analyzed using the principles of framework
analysis to organize the data and identify emerging cat-
egories and key themes or concepts using NVivo v.8
[38]. If the intended sample (n = 24) fails to provide a
rounded picture and redundancy, additional participants
will be interviewed until this is the case.
Sample frame for selection of participants for qualitative
interviews
We will start selecting patients for interview after
recruiting 25% of the target number of patients for
the study, that is after the first 36 patients. All patients
interviewed will have been randomized to the PaDSMaP
self-medicating arm of the study. The logic behind the
criteria is:
 Gender can influence the relative efficacy of
analgesics, may represent differing attitudes to being
in pain and to taking medications to control pain.
 Pain expectation may predict post-operative pain
levels.
 Length of stay as a representation of a combined
measure of pain levels, activity and mobility, and
ability to cope relatively independently after the
operation.
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for example work or retirement. This may influence
decisions to have the operation in the first place,
expectations of functionality afterwards and
activities likely to be undertaken.
Healthcare professionals will be recruited following the
patient interviews and will include ward sisters, ward
nurses, physiotherapists, pharmacists and members of the
pain team. We aim to recruit 12 staff. They will all have
treated at least one patient in the PaDSMaP arm and one
in the TAU arm. Owing to the difficulty of retaining ano-
nymity of comments in such a small pool of professionals
we will refer to staff as either being nurses or allied health
professionals (AHPs) in publications.
Project timetable
The project will take place over 3 years (36 months) in-
cluding preparation and write-up/dissemination time.
The Research Ethics and Research Governance
approvals process will start 6 months before the start of
the study to allow all approvals to be secured before the
study starts.
Research set-up (minus 6 months to start) will include
preparing and submitting ethics and research and devel-
opment (R&D) applications, refining and finalizing re-
search protocols (minus 6 months to start), recruiting
and training the research nurse in the protocol and con-
sent procedures, and setting up research sites (Months 1
to 4).
One hundred and forty-four patients will be identified
for the study by the surgical consultants (approximately
6 weeks prior to surgery), and given information sheets
and consent forms. They will then be recruited to the
study, consented, randomized and baseline information
taken by the research nurse at the pre-operative assess-
ment clinic in one 90 minute session per patient (ap-
proximately 2 to 3 weeks prior to surgery). Patients
allocated to the PaDSMaP arm will also be educated
in self-administration of analgesia at this clinic (20
minutes). After surgery, the patients will be given
appropriate intervention and assessed daily for 3 days
post-operatively or until discharged home, whichever is
sooner. The patients will be followed up at the post-
operative clinic (6 weeks post-surgery) and the final data
will be collected in 30 minute interviews per patient by
the research nurse (patients will be recruited in Months
1 to 24).
Thirty minute one-to-one interviews will be conducted
by the nurse researcher with a subsample of 12 patients
from the PaDSMaP arm and 12 healthcare professionals.
Patient interviews will be conducted in their homes after
the 6 week post-operative clinic has been conducted
(Months 3 to 24) and healthcare professional interviewswill occur after the majority of participants have passed
through the protocols (Months 20 to 26) in a private
room at the hospital.
Data entry cleaning and analysis (Months 30 to 36)
Reports and dissemination will include publication of
the trial protocol (Month 0), a newsletter to trial partici-
pants summarizing the trial’s results, attendance at con-
ferences and publication in relevant peer-reviewed
medical journals (Months 34 to 36). The trial will be
reported in line with Consolidated Standards of Report-
ing Trials (CONSORT) 2010 guidelines [39].
Patients in this cohort will continue to be followed up,
as is standard practice, and their pain (VAS), ADL
(OKS) and QOL (EQ-5D) will be audited up to 5 years
post-operatively. (Since this is part of standard practice
and all data can be anonymized, no additional consent is
required.)
Discussion
Nurse-originated clinical research leading to a rando-
mized clinical trial is unusual. PaDSMaP is such a trial
and although involves orthopaedic patients, it is very
much clinical nurse research in emphasis. Whilst the
primary outcome for PaDSMaP is pain levels at dis-
charge or after 3 days, whichever is sooner, the second-
ary outcomes and associated information gained from
the study will have important implications for patient
care. PaDSMaP is more than just a study looking at the
levels of pain relief and comparing self-medicating
patients with nurse drug rounds; it is also about under-
standing the views of all the stakeholders on the accept-
ability of self-medication. The study aims to show
whether patients’ management of pain improves QOL
and time to mobilize.
The idea that patients should self-medicate in hospi-
tals raises a number of concerns by staff, especially with
ward nurses and pharmacists. The main concerns are
patients overdosing on opiate analgesics, as well as their
ability to look after themselves following a major oper-
ation. In certain specialties where self-medication is
already in place, overdosage is not a reported problem.
Following an operation, self-medication is delayed until
the patient is alert and well enough to do so. The new
enhanced recovery programs for surgery include anaes-
thetic techniques designed to minimize delirium, as well
as nausea and vomiting to allow early (day of operation)
mobilization. In addition, patients are expected to self-
medicate at home, and the ward environment is an ex-
cellent place to check on the correct usage and under-
standing of the medications patients take home.
Regardless of the qualitative outcomes, self-medication
may not be acceptable to an NHS with reduced
resources, unless it proves itself to be cost-effective, for
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has a positive effect on length of stay, time to
mobilization and adverse effects. The range of measures
used in this study aim to give a rounded view on the effi-
cacy of self-administration from both economic, patient
and staff perspectives. The qualitative interviews aim to
uncover the blocks to implementing this change and will
provide valuable insight into the appropriate patient
groups where self-medication can be a successful
intervention.
Developing the PaDSMaP study has already resulted in
the creation of standard operating procedures (SOPs) in
self-medicating for the pharmacy and wards, plus in-
structional booklets on self management of pain and the
various drugs involved. This package can be used in
other settings where self-administration may be pro-
posed and provides a template for similar packages for
other medical conditions.
The trial does have a problem with generalizability. It is
a single hospital, single ward study in a mainly rural area
with an overwhelmingly English-speaking population. It is
also focused on patients undergoing TKR, which was
chosen because of the longer length of stay and higher
pain levels than total hip replacement or unicompartmen-
tal knee replacement. However, it is the nature of the
NHS that developments occur all the time. The NERP
was introduced soon after the inception of this study and
this has shortened the inpatient stay. It is also used for
the majority of patients and again this affects the
generalizability. NERP standardizes care and so may re-
duce the advantages (or otherwise) of self-medication. It
does, however, reduce the variation in pain management,
which was typical only 2 or 3 years ago.
Conclusions
The single center randomized controlled PaDSMaP trial
is designed to look at the efficacy and safety patient self-
medicating analgesia following TKR. The trial includes a
qualitative element and aims to create a package that
can be used to roll out the process in other hospitals.
Trial status
Recruitment started in July 2011. The study is recruiting
to time and target, with recruitment closure anticipated
for May 2013.
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